Tashkent

Tashkent is rapidly emerging as the premier life sciences hub of Central Asia, anchored by the ambitious Tashkent Pharma Park, an innovative industrial cluster designed to integrate R&D with high-tech manufacturing.

The city is best known for its aggressive pharmaceutical sector expansion, transitioning from generic production to the localization of innovative drug formulations through strategic partnerships with global leaders from South Korea, Turkey and Europe.

In the realm of biotechnology, Tashkent is investing heavily in vaccine development and biosimilars, supported by the state-of-the-art Research and Development Center for Medicines.

The healthcare innovation landscape is further bolstered by the "Digital Uzbekistan – 2030" strategy, which has integrated SNOMED CT standards to create a world-class, interoperable digital health ecosystem.

Academic research in the region is centralized around the Pharmaceutical Technical University, which collaborates with international institutions to foster a highly skilled workforce in clinical trial management and drug discovery.

As the government enforces mandatory GMP (Good Manufacturing Practice) and GCP (Good Clinical Practice) certifications by 2026, the city is aligning its regulatory framework with global ICH guidelines.

Tashkent’s medical device sector is also seeing a surge, particularly in the production of specialized equipment for cardiology, oncology and traumatology.

With its strategic geographic location, the city serves as a critical gateway for biopharma companies seeking to access the broader CIS and Eurasian markets.

Ultimately, Tashkent’s fusion of foreign direct investment, specialized free economic zones and a growing clinical research infrastructure positions it as a top-tier destination for global life sciences collaboration.